{
      "Rank": 315,
      "Acronym": [
            "BOOST2B"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database",
            "Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight."
      ],
      "ArmGroupInterventionName": [
            "Biological: BOOST cells"
      ],
      "ArmGroupLabel": [
            "Prospective Control (Untreated) and historical controls",
            "Treatment"
      ],
      "ArmGroupType": [
            "No Intervention",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04623606"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "An exploratory, open label, multiple dose, phase I/II trial (n=15) evaluating safety and efficacy of intravenous and intraosseous infusion of allogeneic expanded fetal mesenchymal stem cells (MSC) for the treatment of severe Osteogenesis Imperfecta (OI) compared with historical and untreated prospective controls."
      ],
      "BriefTitle": [
            "Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones"
      ],
      "CentralContactEMail": [
            "madhuriwalter@cmcvellore.ac.in",
            "brittlebonekids@cmcvellore.ac.in"
      ],
      "CentralContactName": [
            "Vrisha Madhuri, MS Orth",
            "Suhasini Ganesh, M.Pharm"
      ],
      "CentralContactPhone": [
            "91-416-2282172",
            "91-416-2285117"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER_GOV",
            "OTHER_GOV",
            "OTHER"
      ],
      "CollaboratorName": [
            "Ministry of Science and Technology, India",
            "Vinnova",
            "Karolinska Institutet"
      ],
      "CompletionDate": [
            "December 2021"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Osteogenesis Imperfecta"
      ],
      "ConditionAncestorId": [
            "D000010009",
            "D000001848",
            "D000001847",
            "D000009140",
            "D000030342",
            "D000003095",
            "D000003240"
      ],
      "ConditionAncestorTerm": [
            "Osteochondrodysplasias",
            "Bone Diseases, Developmental",
            "Bone Diseases",
            "Musculoskeletal Diseases",
            "Genetic Diseases, Inborn",
            "Collagen Diseases",
            "Connective Tissue Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "BC16",
            "BC17",
            "All",
            "BC18",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "Diseases and Abnormalities at or Before Birth",
            "Skin and Connective Tissue Diseases",
            "All Conditions",
            "Nutritional and Metabolic Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Osteogenesis Imperfecta",
            "Osteogenesis Imperfecta"
      ],
      "ConditionBrowseLeafId": [
            "M12088",
            "M4278",
            "M12084",
            "M11195",
            "M4279",
            "M11249",
            "M22839",
            "M14197",
            "M5475",
            "M5616",
            "T4306",
            "T4309",
            "T3909"
      ],
      "ConditionBrowseLeafName": [
            "Osteogenesis Imperfecta",
            "Bone Diseases",
            "Osteochondrodysplasias",
            "Mucopolysaccharidosis IV",
            "Bone Diseases, Developmental",
            "Musculoskeletal Diseases",
            "Genetic Diseases, Inborn",
            "Rheumatic Diseases",
            "Collagen Diseases",
            "Connective Tissue Diseases",
            "Osteogenesis Imperfecta",
            "Osteogenesis Imperfecta Type III",
            "Mucopolysaccharidosis Type IV"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000010013"
      ],
      "ConditionMeshTerm": [
            "Osteogenesis Imperfecta"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [
            "Historical and Untreated prospective control and Treatment group"
      ],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "(i)Inclusion Criteria Treatment group\n\nParent's/legal guardian's signed informed-consent form\nClinical diagnosis of OI type III or IV AND\nMolecular diagnosis of OI (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene)\nAge between 1 to 4 years\nBP treatment initiated before inclusion\nParent/legal guardian over 18 years of age\n\n(ii)Inclusion Criteria Prospective Untreated Control Group and Historical Control Group:\n\nParent's/legal guardian's signed informed-consent form\nClinical and molecular diagnosis of OI (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene)\nAge between 4 to 8 years\nParent/legal guardian over 18 years of age\n\n(iii)Exclusion Criteria Treatment group Prospective and historical control group:\n\nExistence of other known disorder that might interfere with the treatment (such as severe malformations, congenital heart defect, hypoxic encephalopathy (l-lll), neurological problems, immune deficiencies, muscle diseases, syndromes) diagnosed by clinical examination\nAny contraindication for invasive procedures such as a moderate/severe bleeding tendency or contagious infections\nAbnormal karyotype or other confirmed genetic syndromes\nOncologic disease\nInability to comply with the trial protocol and evaluation and follow-up schedule\nInability to understand the information and to provide informed consent"
      ],
      "EnrollmentCount": [
            "15"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Treatment"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Hemat",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Hematinics",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M10262"
      ],
      "InterventionBrowseLeafName": [
            "Liver Extracts"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "BOOST cells"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "OI, Brittle bone disease",
            "Hereditary bone fragility"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "November 10, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "November 6, 2020"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Christian Medical College, Vellore, India"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Vellore"
      ],
      "LocationContactEMail": [
            "brittlebonekids@cmcvellore.ac.in",
            "brittlebonekids@cmcvellore.ac.in"
      ],
      "LocationContactName": [
            "Suhasini Ganesh, M.Pharm",
            "Suhasini Ganesh, M Pharm"
      ],
      "LocationContactPhone": [
            "91-416-2285117",
            "91-416-2285117"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact"
      ],
      "LocationCountry": [
            "India"
      ],
      "LocationFacility": [
            "Christian Medical College"
      ],
      "LocationState": [
            "Tamil Nadu"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "632004"
      ],
      "MaximumAge": [
            "8 Years"
      ],
      "MinimumAge": [
            "1 Year"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Exploratory, Open Label, Multiple Dose, Phase I/II Trial Evaluating Safety, Efficacy of Intravenous and Intraosseous Infusion of Allogeneic Fetal Mesenchymal Stem In Treatment of Severe Osteogenesis Imperfecta Compared With Historical and Untreated Prospective Controls"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Christian Medical College, Vellore, India"
      ],
      "OrgStudyId": [
            "CMCB2B0X"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [
            "Quality of life assessed using the Infant Pediatric Quality of Life Questionnaire\u2122 (PedsQOL).",
            "Donor cell engraftment.",
            "Paracrine effects will be analysed from plasma isolated from peripheral blood."
      ],
      "OtherOutcomeMeasure": [
            "Impact on the subjects Quality of Life: Pediatric Quality of Life Questionnaire\u2122 (PedsQOL) [ Time Frame: From baseline to the 16 month follow-up",
            "Incidence of donor cells engrafted into patient tissue samples assessed by histology. [ Time Frame: From baseline to the 16 month follow up",
            "Analysis of an array of cytokines and micro vesicles to evaluate paracrine effects. [ Time Frame: From baseline to the 16 month follow up"
      ],
      "OtherOutcomeTimeFrame": [
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up"
      ],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Christian Medical College, Vellore, India"
      ],
      "OverallOfficialName": [
            "Vrisha Madhuri, MS Orth"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "November 2021"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "The primary endpoint is safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)/Serious AE (SAE)/Suspected Unexpected Serious Adverse Reaction (SUSAR)with specific focus on the following:\n\nVital signs in conjunction with the MSC infusion\nTransfusion reactions (infusion toxicity, embolism, allergy, infections)\nImmune reaction towards the cells, donor-specific antibodies, graft rejection, Graft versus Host Disease, autoimmunity)\nTumourigenicity\nMortality/morbidity"
      ],
      "PrimaryOutcomeMeasure": [
            "Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "From baseline to 16 months follow up"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Christian Medical College, Vellore, India"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Vrisha Madhuri"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Professor"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Number of fractures.",
            "Time (days) to first fracture after each stem cell administration. Number of fractures",
            "Change in bone-marrow density (g/cm2).",
            "Growth (cm) as assessed by clinician",
            "Growth (kg) as assessed by clinician.",
            "Change in clinical status of OI based on parameters defined under efficacy assessments described in protocol, as assessed by OI clinician.",
            "Assessment of biochemical bone turnover marker P-Calcium (mg %)",
            "Assessment of biochemical bone turnover marker P-Phosphate (mg %)",
            "Assessment of biochemical bone turnover marker P-Albumin (g/dL)",
            "Assessment of biochemical bone turnover marker S-ALP (IU/L)",
            "Assessment of biochemical bone turnover marker S-CTx (mg %)",
            "Assessment of biochemical bone turnover marker fP-PTH (pg/mL)",
            "Assessment of biochemical bone turnover marker Vitamin D (nmol/L)",
            "Assessment of biochemical bone turnover marker Bone specific S-ALP (\u03bcg/L)",
            "Assessment of biochemical bone turnover marker S-Osteocalcin (ng/mL)",
            "Assessment of biochemical bone turnover marker U-DPD/Krea and U-NTx/Krea (mg %)"
      ],
      "SecondaryOutcomeMeasure": [
            "Number of fractures [ Time Frame: From baseline to 16 months follow-up ]",
            "Time (days) to first fracture after each stem cell administration. [ Time Frame: From each dose of stem cells to the time point of the first fracture.",
            "Change in bone-marrow density (g/cm2). [ Time Frame: From baseline to the primary follow-up (From baseline to 16 months follow up)",
            "Growth (cm). [ Time Frame: From baseline to16 months follow up]",
            "Weight (kg). [ Time Frame: From baseline to 16 months follow up]",
            "Change in clinical status of OI. [ Time Frame: From baseline to 16 months follow up]",
            "Assessment of biochemical bone turnover by analysis of the markers P-Calcium (mg %) in blood samples.",
            "Assessment of biochemical bone turnover by analysis of the markers P-Phosphate (mg %) in blood samples.",
            "Assessment of biochemical bone turnover by analysis of the markers P-Albumin (g/dL)",
            "Assessment of biochemical bone turnover by analysis of the markers S-ALP (IU/L) in blood samples.",
            "Assessment of biochemical bone turnover by analysis of the markers S-CTx (mg %) in blood samples.",
            "Assessment of biochemical bone turnover by analysis of the markers fP-PTH (pg/mL)in blood samples.",
            "Assessment of biochemical bone turnover by analysis of the markers Vitamin D (nmol/L) in blood samples.",
            "Assessment of biochemical bone turnover by analysis of the markers Bone specific S-ALP (\u03bcg/L) in blood samples.",
            "Assessment of biochemical bone turnover by analysis of the markers S-Osteocalcin (ng/mL) in blood samples.",
            "Assessment of biochemical bone turnover by analysis of the markers U-DPD/Krea and U-NTx/Krea (mg %) in blood samples."
      ],
      "SecondaryOutcomeTimeFrame": [
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From at baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up",
            "From baseline to 16 months follow up"
      ],
      "SeeAlsoLinkLabel": [
            "Boost to Brittle Bones"
      ],
      "SeeAlsoLinkURL": [
            "http://boost2b.in/"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 20, 2019"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "November 2020"
      ],
      "StdAge": [
            "Child"
      ],
      "StudyFirstPostDate": [
            "November 10, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "September 18, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "November 6, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}